Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy non-Asian, male or non-lactating, non-pregnant female participants who are 18-65 years of age.~* Clinical laboratory test must be within normal limits or clinically acceptable to the Investigator/Sponsor.~* Participants must have normal or clinically acceptable physical exam and ECG.~* Participants must be free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations, procedures, or participation.~* Able to understand and comply with study procedures required and able and willing to provide written informed consent prior to any study procedures being performed.~Exclusion Criteria:~* History of hypersensitivity, allergy or intolerance to omeprazole, or other proton pump inhibitors~* History of peptic ulcer disease or other acid related gastrointestinal symptoms or heartburn with a frequency of more than one/month.~* Positive H. pylori breath test at screening.~* Participation in any study of an investigational treatment in the 30 days before Screening or participation in another study at any time during the period of this study~* Any significant medical illness that would contraindicate participation in the study~* Gastrointestinal disorder or surgery leading to impaired drug absorption~* Any significant mental illness, such as schizophrenia or bipolar disorder~* History (in the past year) suggestive of alcohol or drug abuse or dependence, or excessive alcohol use (\>2 units per day on average; for example \>2 bottles of beer, \>2 glasses of wine, \>2 ounces of liquor/spirits), or excessive alcohol use during the study~* Any abnormal Screening laboratory value that is clinically significant in the investigator's opinion~* Currently using or use of any prescription or over the counter (OTC) medications that affect gastrointestinal function, including first generation antihistamines (e.g. diphenhydramine) and anticholinergic agents within 7 days prior to 1st treatment administration.~* Currently using, or use within 14 days of first treatment administration, or having a history of frequent use of antacids, OTC or Prescription (Rx) H2 receptor antagonists, or OTC or Rx use of proton pump inhibitors.~* Positive urine drug/alcohol test at Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Zegerid (Type: EXPERIMENTAL): Participants receiving Zegerid (omeprazole/sodium bicarbonate) in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants also took approximately 2 oz of water with their medication.
- Prevacid® (Type: ACTIVE_COMPARATOR): Participants receiving Prevacid® (lansoprazole) in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants also took approximately 2 oz of water with their medication.
- No treatment (Type: NO_INTERVENTION): Participants receiving No treatment in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants took approximately 2 oz of water once daily for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).